Genmab
kr 2,257.00Change from previous close: −2.42%Absolute change: −kr 56.00
At a glance
- Revenue growth
- +19.19%
- 2025 vs 2024
- Net income growth
- −15.00%
- 2025 vs 2024
- Net margin
- 25.9%
- 2024: 36.3%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 1,186 | 1,126 | 1,071 | 562 | 341 |
| Depreciation and amortization | 57.0 | 52.0 | 43.0 | 52.0 | 29.7 |
| Capital expenditure | -37.0 | -27.0 | -53.0 | -45.5 | -38.5 |
| Investing cash flow | -5,643 | -1,447 | -185 | -397 | -147 |
| Financing cash flow | 4,789 | -566 | -89.0 | -113 | -64.2 |
| Share repurchases | -448 | -576 | -96.0 | -143 | -76.0 |
| Debt repaid | -13.0 | -9.0 | — | -10.5 | — |
| Effect of exchange rates | 3.0 | 63.0 | -12.0 | 82.5 | 130 |
| Net change in cash | 335 | -824 | 785 | 134 | 260 |
| Free cash flow | 1,149 | 1,099 | 1,018 | 517 | 302 |
| Levered free cash flow | 1,068 | 915 | 778 | 305 | 260 |